All In Biotech

NDA 208464 · Gilead Sciences INC

Vemlidy

Tenofovir Alafenamide Fumarate · Oral

Last checked: Nov 20, 2026Latest source record: Mar 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Nov 10, 2016

Approved uses

9

Original approval plus efficacy supplements

Registered trials

339

91 Phase 3, 31 recruiting

FAERS reports

4,168

2,952 serious, 436 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Discontinuation of anti-hepatitis B therapy may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely in patients who discontinue VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted. ( 5.1 )

What it is approved for

From the label in effect Jul 14, 2025.

VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease [see Clinical Studies (14) ] . VEMLIDY is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease. ( 1 )

Mechanism: Tenofovir alafenamide is an antiviral drug against the hepatitis B virus [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 27, 2024 Supplement 16 · Efficacy · priority review LetterLabel
  • Mar 27, 2024 Supplement 17 · Efficacy LetterLabel
  • Oct 17, 2022 Supplement 14 · Efficacy · priority review LetterLabel
  • Aug 18, 2020 Supplement 10 · Efficacy LetterLabel
  • Aug 18, 2020 Supplement 11 · Efficacy LetterLabel
  • Feb 4, 2020 Supplement 8 · Efficacy LetterLabel
  • Feb 4, 2019 Supplement 7 · Efficacy LabelLetter
  • Jul 3, 2018 Supplement 4 · Efficacy Letter
  • Nov 10, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • VEMLIDY · TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tenofovir Alafenamide" as an intervention, any sponsor and status, largest first.

All 339 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death254
  • product dose omission issue184
  • off label use172
  • fatigue144
  • drug ineffective125
  • diarrhoea96
  • headache92
  • nausea92
  • drug interaction89
  • product use issue88
  • neoplasm malignant72
  • rash72

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20163
2017108
2018310
2019513
2020413
2021536
2022551
2023510
2024473
2025419
2026331

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vemlidy (Tenofovir Alafenamide)

2024 spending

$199M

Beneficiaries

14,948

128,867 claims

Per beneficiary

$13,312

$47.42 per unit

View as table
YearSpending
2020$127,209,285
2021$137,298,226
2022$158,415,546
2023$187,858,704
2024$198,986,501

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 315 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.